{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:16:26Z","timestamp":1790957786513,"version":"4.1.0"},"reference-count":44,"publisher":"Cambridge University Press (CUP)","issue":"5","license":[{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100014605","name":"Sage Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014605","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Spectr."],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Major depressive disorder (MDD) is a leading contributor to disability worldwide and is associated with increased morbidity and mortality. Current pharmacologic treatment options may be ineffective for some patients and can pose several limitations and challenges, including suboptimal response and slow onset of action. Many of these therapies can take 6 to 8 weeks for patients to achieve response and 12 weeks or longer to demonstrate full clinical benefit. Delays in depressive symptom resolution are associated with poor symptomatic and functional outcomes, decreased quality of life, and increased burden on the healthcare system. Achieving response and remission of symptoms soon after diagnosis and treatment is associated with lower rates of relapse and a greater likelihood of functional recovery. An unmet need exists for innovative treatments that offer rapid and sustained effects. This editorial discusses the benefits of rapid improvement in depressive symptoms with available and investigational agents for patients with MDD.<\/jats:p>","DOI":"10.1017\/s1092852923002213","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T22:14:58Z","timestamp":1679868898000},"page":"521-525","source":"Crossref","is-referenced-by-count":10,"title":["Importance of achieving rapid treatment response in major depressive disorder"],"prefix":"10.1017","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9742-398X","authenticated-orcid":false,"given":"Gustavo","family":"Alva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2023,3,27]]},"reference":[{"key":"S1092852923002213_r4","unstructured":"4. American Psychological Association. Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts. https:\/\/www.apa.org\/depression-guideline. Accessed January 16, 2023."},{"key":"S1092852923002213_r5","doi-asserted-by":"publisher","DOI":"10.4068\/cmj.2018.54.2.101"},{"key":"S1092852923002213_r38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032994"},{"key":"S1092852923002213_r42","unstructured":"42. Clayton, AH , Lasser, R , Brown, C , et al. Zuranolone in major depressive disorder: results from the phase 3, multicenter, randomized, double-blind, placebo-controlled, WATERFALL study. Paper presented at: Psych Congress; October 29-November 1, 2021, San Antonio, TX."},{"key":"S1092852923002213_r40","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b00846"},{"key":"S1092852923002213_r21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02080-3"},{"key":"S1092852923002213_r2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2006.163.11.1905"},{"key":"S1092852923002213_r43","doi-asserted-by":"crossref","unstructured":"43. Cutler, AJ , Aaronson, ST , Mattingly, GW , et al. Safety, tolerability, and efficacy of zuranolone repeat treatment courses in adult patients with major depressive disorder\u2014an analysis of the open-label, phase 3 SHORELINE study. Poster presented at: Psych Congress; 2022, New Orleans, LA.","DOI":"10.4088\/JCP.23m14845"},{"key":"S1092852923002213_r28","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2020.3285"},{"key":"S1092852923002213_r32","doi-asserted-by":"publisher","DOI":"10.1016\/j.brs.2021.11.010"},{"key":"S1092852923002213_r39","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108333"},{"key":"S1092852923002213_r19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31264-3"},{"key":"S1092852923002213_r6","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-13-51"},{"key":"S1092852923002213_r3","first-page":"1","article-title":"American Psychiatric Association practice guideline for the treatment of patients with major depressive disorder","volume":"167","author":"Gelenberg","year":"2010","journal-title":"Am J Psychiatry"},{"key":"S1092852923002213_r14","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2012.12050648"},{"key":"S1092852923002213_r1","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12301"},{"key":"S1092852923002213_r23","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.21m14345"},{"key":"S1092852923002213_r37","unstructured":"37. U.S. Food and Drug Administration. FDA approves first treatment for post-partum depression. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-post-partum-depression. Accessed January 30, 2023."},{"key":"S1092852923002213_r20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31551-4"},{"key":"S1092852923002213_r16","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0406"},{"key":"S1092852923002213_r25","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14m09688"},{"key":"S1092852923002213_r29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815981"},{"key":"S1092852923002213_r36","unstructured":"36. Auvelity. Prescribing Information. Axsome Therapeutics, Inc.; October 2022. https:\/\/www.axsome.com\/auvelity-prescribing-information.pdf. Accessed January 16, 2023."},{"key":"S1092852923002213_r11","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2008.10.4\/kkelly"},{"key":"S1092852923002213_r15","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2020.00080"},{"key":"S1092852923002213_r9","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.4103\/0019-5545.196973","article-title":"Clinical practice guidelines for the management of depression","volume":"59","author":"Gautam","year":"2017","journal-title":"Indian J Psychiatry."},{"key":"S1092852923002213_r18","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2021.20101429"},{"key":"S1092852923002213_r10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2022.09.162"},{"key":"S1092852923002213_r17","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2017.04.005"},{"key":"S1092852923002213_r33","doi-asserted-by":"publisher","DOI":"10.1016\/j.chc.2018.07.003"},{"key":"S1092852923002213_r8","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201400021"},{"key":"S1092852923002213_r13","unstructured":"13. U.S. Food and Drug Administration. Major depressive disorder: developing drugs for treatment (June 2018). https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/major-depressive-disorder-developing-drugs-treatment. Accessed January 30, 2023."},{"key":"S1092852923002213_r12","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-021-01021-w"},{"key":"S1092852923002213_r44","unstructured":"44. Cutler, AJ , Aaronson, ST , Mattingly, GW , et al. Safety and efficacy of zuranolone 50 mg and need for repeat treatment courses in the open-label, phase 3 SHORELINE study of adult patients with major depressive disorder. Poster presented at: Psych Congress; 2022, New Orleans, LA."},{"key":"S1092852923002213_r24","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n0604"},{"key":"S1092852923002213_r30","unstructured":"30. Clayton, AH , Deligiannidis, KM , Lasster, R , et al. Sustained benefits of zuranolone in patients with major depressive disorder: results from the LANDSCAPE clinical development program. Paper presented at: Psych Congress; September 17-20, 2022; New Orleans, LA."},{"key":"S1092852923002213_r31","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2021.1559"},{"key":"S1092852923002213_r7","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291709006011"},{"key":"S1092852923002213_r26","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04629"},{"key":"S1092852923002213_r35","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2018.1483"},{"key":"S1092852923002213_r27","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145710000015"},{"key":"S1092852923002213_r22","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.13030392"},{"key":"S1092852923002213_r34","doi-asserted-by":"publisher","DOI":"10.1016\/j.psc.2018.04.006"},{"key":"S1092852923002213_r41","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00801-0"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852923002213","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T22:03:49Z","timestamp":1729116229000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852923002213\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,27]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S1092852923002213"],"URL":"https:\/\/doi.org\/10.1017\/s1092852923002213","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,27]]}}}